NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
Clinical Trials
7 trialsNCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003057 2023-06-18
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003283 2023-06-15
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00002864 2020-04-01
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00075868 2015-11-17
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00227773 2015-10-08
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Withdrawn